Chaten D Jessel1, Sam Mostafa2,3, Maria Potiriadis4, Ian P Everall5,6,7, Jane M Gunn4, Chad A Bousman1,6,8,9. 1. Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. 2. MyDNA Life, Australia Limited, South Yarra. 3. Centre for Medicine Use and Safety, Monash University. 4. Department of General Practice, The University of Melbourne, Parkville, VIC, Australia. 5. Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. 6. Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia. 7. South London and Maudsley NHS Foundation Trust, London, UK. 8. Department of Medical Genetics, Psychiatry, Physiology & Pharmacology, University of Calgary. 9. Alberta Children's Hospital Research Institute, Calgary, AB, Canada.
Abstract
OBJECTIVE: To describe the usage patterns of antidepressants with published CYP2D6- and CYP2C19-based prescribing guidelines among depressed primary care patients and estimate the proportion of patients taking antidepressants not recommended for them based on their CYP2C19 and CYP2D6 genotype-predicted metabolizer status. METHODS: Medication use and pharmacogenetic testing results were collected on 128 primary care patients enrolled in a 10-year depression cohort study. At each 12-month interval, we calculated the proportion of patients that: (1) reported use of one or more of the 13 antidepressant medications (i.e. amitriptyline, citalopram, escitalopram, clomipramine, desipramine, doxepin, fluvoxamine, imipramine, nortriptyline, paroxetine, sertraline, trimipramine, venlafaxine) with published CYP2D6- and CYP2C19-based prescribing guidelines, (2) were taking an antidepressant that was not recommended for them based on their CYP2C19 and CYP2D6 genotype-predicted metabolizer phenotype, and (3) switched medications from the previous 12-month interval. RESULTS: The annual proportion of individuals taking an antidepressant with a CYP2D6- and CYP2C19-based prescribing guidelines ranged from 45 to 84%. The proportion of participants that used an antidepressant that was not recommended for them, based on available CYP2D6 and CYP2C19 metabolizer phenotype, ranged from 18 to 29% and these individuals tended to switch medications more frequently (10%) compared to their counterparts taking medication aligned with their metabolizer phenotype (6%). CONCLUSION: One-quarter of primary care patients used an antidepressant that was not recommended for them based on CYP2D6- and CYP2C19-based prescribing guidelines and switching medications tended to be more common in this group. Studies to determine the impact of CYP2D6 and CYP2C19 genotyping on reducing gene-antidepressant mismatches are warranted.
OBJECTIVE: To describe the usage patterns of antidepressants with published CYP2D6- and CYP2C19-based prescribing guidelines among depressed primary care patients and estimate the proportion of patients taking antidepressants not recommended for them based on their CYP2C19 and CYP2D6 genotype-predicted metabolizer status. METHODS: Medication use and pharmacogenetic testing results were collected on 128 primary care patients enrolled in a 10-year depression cohort study. At each 12-month interval, we calculated the proportion of patients that: (1) reported use of one or more of the 13 antidepressant medications (i.e. amitriptyline, citalopram, escitalopram, clomipramine, desipramine, doxepin, fluvoxamine, imipramine, nortriptyline, paroxetine, sertraline, trimipramine, venlafaxine) with published CYP2D6- and CYP2C19-based prescribing guidelines, (2) were taking an antidepressant that was not recommended for them based on their CYP2C19 and CYP2D6 genotype-predicted metabolizer phenotype, and (3) switched medications from the previous 12-month interval. RESULTS: The annual proportion of individuals taking an antidepressant with a CYP2D6- and CYP2C19-based prescribing guidelines ranged from 45 to 84%. The proportion of participants that used an antidepressant that was not recommended for them, based on available CYP2D6 and CYP2C19 metabolizer phenotype, ranged from 18 to 29% and these individuals tended to switch medications more frequently (10%) compared to their counterparts taking medication aligned with their metabolizer phenotype (6%). CONCLUSION: One-quarter of primary care patients used an antidepressant that was not recommended for them based on CYP2D6- and CYP2C19-based prescribing guidelines and switching medications tended to be more common in this group. Studies to determine the impact of CYP2D6 and CYP2C19 genotyping on reducing gene-antidepressant mismatches are warranted.
Authors: O S Bryushinina; Yu G Zyuz'kova; E A Yanovskaya; N Y Abdrashitova; G A Frelikh; A P Lakeev; D V Tsuran; V V Udut; G N Zyuz'kov Journal: Bull Exp Biol Med Date: 2021-12-02 Impact factor: 0.804
Authors: Heather D Anderson; Thida M Thant; David P Kao; Kristy R Crooks; Nicholas D Mendola; Christina L Aquilante Journal: Clin Transl Sci Date: 2022-04-29 Impact factor: 4.438
Authors: Liv S Thiele; Kazi Ishtiak-Ahmed; Janne P Thirstrup; Esben Agerbo; Carin A T C Lunenburg; Daniel J Müller; Christiane Gasse Journal: Pharmaceuticals (Basel) Date: 2022-07-14